Mevastatin induced apoptosis in U266 human myeloma cells;Apoptózis indukálása mevastatinnal humán U266 myeloma sejtvonalon

Magyar Onkologia

Volumn 48, Issue 4, 2004, Pages 333-337

  Judit, Jánosi ^a   Anna, Sebestyén ^b   József, Bocsi ^b   Gábor, Barna ^b   Katalin, Nagy ^b   István, Vályi Nagy ^a   László, Kopper ^b  

^a Hematológiai és Hemosztazeológiai Osztály ^*  (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; BCL2L1 PROTEIN, HUMAN; COMPACTIN; DRUG DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMBRANE PROTEIN; MEVINOLIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEOGLYCAN; SDC1 PROTEIN, HUMAN; SYNDECAN; SYNDECAN 1;

APOPTOSIS; ARTICLE; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION REGULATION; HUMAN; MULTIPLE MYELOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; PROTEOGLYCANS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYNDECAN-1; SYNDECANS;

EID: 15744382525     PISSN: 00250244     EISSN: 20600399     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Agarwal B, Halmos B, Moss SF, et al. Lovastatin sensitizes colon cancer HT-29 cells to apoptosis induced by chemotherapeutic agents. Proc Am Assoc Cancer Res 39:68, 1998
2. Alberts AW. Discovery, biochemistry and biology oflovastatin. Am J Cardiol 62:10J-15J, 1988
3. Dhodapkar M, Abe E, Theus A, et al. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor survival, growth and bone cell differentation. Blood 91:2679-2688, 1998
4. Dimitroulakos J, Thai S, Wasfy GH, et al. Lovastatin induces a pronounced differentation response in acute myeloid leukemia. Leuk Lymphoma 40:167-178, 2000
5. Jakobiosal M, Bruno S, Skierski JS, Darzynkiewicz Z. Cell cycle-specific effect of lovastatin. Proc Nat Acid Sci (Wash) 88:3628-3632, 1991
6. Jánosi J, Sebestyén A, Mikala G, et al. Soluble syndecan-1 levels in different plasma cell dyscrasias and different stages of multiple myeloma. Haematologica 89:370-371, 2004
7. Kawata S, Yamasaki E, Naogese E, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 84: 886-891, 2001
8. Kim WS, Kim HM, Choi HJ, et al. Phase II study of highdose lovastatin in patients with advenced gastric adenocarcinoma. Invest New Drugs 19:81-83, 2001
9. Korman L, Borysink L. Replacing lovastatin with pravastatin: effect on serum lipids and cost. Am J Health Syst Pharm 52:1078-1082, 1995
10. Kusama T, Mukai M, Iwasaki T, et al. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastatis. Gastroenterol 122: 308-317, 2002
11. Minden MD, Dimitroulakos J, Notrynek D, Penn LZ. Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia. Leuk Lymphoma 40:659-662, 2001
12. Mitsiades N, Mitsiades CS, Poulaki V, et al. Intracellular regulation of tumor necrosis factor-related apoptosisinducing ligand-induced apoptosis in human multiple myeloma cells. Blood 99:2162-2171, 2002
13. Nashimoto N, Shina Y, Yoshizaki K, Kishimoto T. Myeloma biology and therapy: present status and future developments. Haematol Oncol Clin North Am 11:159-172, 1997
14. Park C, Lee I, Kang WK. Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death. Carcinogenesis 10:1727-1731, 2001
15. Pederson TR, Berge K, Cook TJ, et al. Safety and tolarability of cholesterol lowering agents with simvastatin during 5 years in Scandinavian Simvastatin Survival Study. Arch Intern Med 156:3085-3092, 1996
16. Ridley R, Xiao H, Hata H, et al. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 81:767-774, 1993
17. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patient with average cholesterol level. Cholesterol and Recurrent Event Trial Investigators. N Engl J Med 335:1001-1009, 1996
18. Seidel C, Sundan A, Hjoth M, et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95:388-392, 2000
19. Sumi S, Beauchamp Rd, Townsend CM, et al. Lovastatin inhibits pancreatic cancer growth regard less of RAS mutation. Pancreas 5:657-661, 1994
20. Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonat pathway, in patient with cancer. Clin Cancer Res 2:483-491, 1996
21. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 267:1456-1462, 1995
22. Tu Y, Renner S, Xu F, et al. BCL-XL expression in multiple myeloma, possible indicator of chemoresistance. Cancer Res 58:256-262, 1998
23. Van De Donk NW, Kamphuis MM, Lakhorsz HM, Bloem AC. The cholesterol lowering drug lovastatin induced cell death in myeloma plasma cells. Leukemia 16:1362-1371, 2002
24. Wachtershauser A, Akoglen B, Stein J. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line CaCo2. Carcinogenesis 22:1061-1067, 2001
25. Wickremosingle R, Hoffbrand AV. Biochemical and genetic control of apoptosis relevance to normal haematopoesis and haematological malignancies. Blood 93:3587-3600, 1999
26. Wijdenes J, Vooijis WC, Clement C, et al. A plasmocyte selectiv monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 94:318-323, 1996
27. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16:508-519, 2002
28. Xia Z, Tan M, Wong WW. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 9:1398-1407, 2001